ClinicalTrials.gg
Sign In
Drug

BI 765423 clinical trials

Also written BI 765423.

studies test it
3
open now
0
in phase 3
0
first study started
2023

How each study uses BI 765423 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

BI 765423
3

Studies by the year they started

3 studies that test it; most in 2023 (1)

Studies that test BI 765423, by start year
YearStudies
20231
20241
20251

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Idiopathic Pulmonary Fibrosis
1

Who runs them

Industry 3 · Other 0

Boehringer Ingelheim (3)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test BI 765423.

Studies

Open first, then newest update. How each study uses BI 765423 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3